Clinical and biochemical evaluation of rituximab as add on therapy in neuromyelitis optica spectrum disorders.

AbstractObjectiveMethodsResultsConclusionThis study assesses the efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders (NMOSD).The study initially included 40 patients with NMOSD diagnosed, after excluding patients who did not meet the complete inclusion criteria. Patients in the conventional group received routine clinical treatment, while patients in the study group received additional treatment with rituximab on the basis of the conventional treatment. Baseline data and clinically relevant indicators were collected for all patients, and the efficacy was compared between the two groups.Baseline data were comparable between the two groups (<italic>p</italic> > 0.05). The EDSS scores after clinical treatment in the study group were lower than those in the conventional group, and the difference in EDSS scores before and after treatment was higher than that in the conventional group (<italic>p</italic> < 0.05). The difference in visual acuity correction before and after treatment was not significant between the two groups (<italic>p</italic> > 0.05). Laboratory indicators in the study group after clinical treatment were superior to those in the conventional group (all <italic>p</italic> < 0.05). The recurrence rate after clinical treatment in the study group was significantly lower than that in the conventional group (<italic>p</italic> < 0.05). Adverse reactions after clinical treatment in the study group were less than those in the conventional group (<italic>p</italic> < 0.05).This study found that rituximab demonstrated significant efficacy in the acute attacks and recurrence prevention of NMOSD, emphasizing its relatively good safety and tolerability. It highlights the potential of rituximab in treating NMOSD and provides valuable insights for future disease management. [ABSTRACT FROM AUTHOR]